Does the media prefer PTGX or ONC?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat Protagonist Therapeutics' score of 0.67 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or PTGX?

In the previous week, Moderna had 14 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 24 mentions for Moderna and 10 mentions for Protagonist Therapeutics. Moderna's average media sentiment score of 0.82 beat Protagonist Therapeutics' score of 0.67 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or ROIV?

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Protagonist Therapeutics' score of 0.67 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INSM or PTGX?

In the previous week, Insmed had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 10 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 0.94 beat Protagonist Therapeutics' score of 0.67 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or PTGX?

In the previous week, Protagonist Therapeutics had 4 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat Protagonist Therapeutics' score of 0.67 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Protagonist Therapeutics (PTGX) Competitors

$129.89 -1.53 (-1.16%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$129.88 -0.01 (-0.01%)

As of 07/13/2026 07:32 PM Eastern

Compare

PTGX vs. ONC, MRNA, ROIV, INSM, and BNTX

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Protagonist Therapeutics compare to BeOne Medicines?

Protagonist Therapeutics (NASDAQ:PTGX) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Protagonist Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00

Protagonist Therapeutics currently has a consensus price target of $116.93, indicating a potential downside of 9.98%. BeOne Medicines has a consensus price target of $391.38, indicating a potential upside of 28.76%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Protagonist Therapeutics had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat Protagonist Therapeutics' score of 0.67 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Protagonist Therapeutics' net margin of -154.88%. BeOne Medicines' return on equity of 12.06% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Protagonist Therapeutics has lower revenue, but higher earnings than Moderna. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A

Moderna has a net margin of -143.55% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Moderna currently has a consensus target price of $38.27, suggesting a potential downside of 42.89%. Protagonist Therapeutics has a consensus target price of $116.93, suggesting a potential downside of 9.98%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Moderna had 14 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 24 mentions for Moderna and 10 mentions for Protagonist Therapeutics. Moderna's average media sentiment score of 0.82 beat Protagonist Therapeutics' score of 0.67 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	11 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Protagonist Therapeutics presently has a consensus price target of $116.93, indicating a potential downside of 9.98%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 2.66%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protagonist Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -3,629.19%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Protagonist Therapeutics' score of 0.67 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Insmed has a net margin of -144.44% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Protagonist Therapeutics has lower revenue, but higher earnings than Insmed. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A

Insmed currently has a consensus target price of $211.00, indicating a potential upside of 93.33%. Protagonist Therapeutics has a consensus target price of $116.93, indicating a potential downside of 9.98%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

In the previous week, Insmed had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 10 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 0.94 beat Protagonist Therapeutics' score of 0.67 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Protagonist Therapeutics has lower revenue, but higher earnings than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.02	-$1.29B	-$5.88	N/A
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A

BioNTech presently has a consensus target price of $129.13, suggesting a potential upside of 43.36%. Protagonist Therapeutics has a consensus target price of $116.93, suggesting a potential downside of 9.98%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Protagonist Therapeutics had 4 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat Protagonist Therapeutics' score of 0.67 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Summary

BioNTech and Protagonist Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.45B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-71.76	20.85	27.15	24.26
Price / Sales	181.51	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	13.21	8.49	10.75	6.29
Net Income	-$130.15M	$23.83M	$3.58B	$330.66M
7 Day Performance	-7.78%	-3.56%	-2.07%	-1.32%
1 Month Performance	18.32%	6.31%	3.31%	-0.64%
1 Year Performance	135.18%	48.30%	26.35%	19.08%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.5561 of 5 stars	$129.89 -1.2%	$116.93 -10.0%	+145.1%	$8.45B	$46.02M	N/A	120
ONC BeOne Medicines	4.6744 of 5 stars	$298.70 -1.4%	$391.38 +31.0%	+21.4%	$33.23B	$5.34B	66.82	12,000
MRNA Moderna	1.8577 of 5 stars	$68.27 -10.8%	$38.27 -43.9%	+99.2%	$30.38B	$1.94B	N/A	4,700	Options Volume
ROIV Roivant Sciences	1.544 of 5 stars	$35.97 -2.3%	$33.59 -6.6%	+203.8%	$26.48B	$8.26M	N/A	860
INSM Insmed	4.0914 of 5 stars	$115.61 -2.2%	$211.00 +82.5%	+11.2%	$25.63B	$606.42M	N/A	1,664	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. ONC, MRNA, ROIV, INSM, and BNTX

How does Protagonist Therapeutics compare to BeOne Medicines?

Summary

How does Protagonist Therapeutics compare to Moderna?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. ONC, MRNA, ROIV, INSM, and BNTX

How does Protagonist Therapeutics compare to BeOne Medicines?

Which has more risk and volatility, PTGX or ONC?

Do insiders & institutionals have more ownership in PTGX or ONC?

Which has stronger earnings & valuation, PTGX or ONC?

Do analysts prefer PTGX or ONC?

Does the media prefer PTGX or ONC?

Is PTGX or ONC more profitable?

Summary

How does Protagonist Therapeutics compare to Moderna?

Which has stronger earnings and valuation, MRNA or PTGX?

Is MRNA or PTGX more profitable?

Do analysts recommend MRNA or PTGX?

Which has more risk & volatility, MRNA or PTGX?

Do institutionals and insiders have more ownership in MRNA or PTGX?

Does the media favor MRNA or PTGX?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Do analysts rate PTGX or ROIV?

Which has more risk & volatility, PTGX or ROIV?

Is PTGX or ROIV more profitable?

Do institutionals & insiders believe in PTGX or ROIV?

Which has preferable earnings & valuation, PTGX or ROIV?

Does the media refer more to PTGX or ROIV?

Summary

How does Protagonist Therapeutics compare to Insmed?

Do institutionals & insiders hold more shares of INSM or PTGX?

Is INSM or PTGX more profitable?

Which has preferable earnings and valuation, INSM or PTGX?

Do analysts rate INSM or PTGX?

Which has more volatility and risk, INSM or PTGX?

Does the media favor INSM or PTGX?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Which has better earnings and valuation, BNTX or PTGX?

Do analysts prefer BNTX or PTGX?

Does the media favor BNTX or PTGX?

Do insiders and institutionals hold more shares of BNTX or PTGX?

Which has more risk & volatility, BNTX or PTGX?

Is BNTX or PTGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools